Novel combinatorial hormone therapies are being researched at the pre-clinical stage for obesity treatment (216), wherein the novel unimolecular GLP-1R/GIPR/GCGR triagonist at a very low dose of 2 nmol/kg decreases cumulative food intake and reduces the body weight of HFD-mice by 18.3% and is more effective than any other available therapy (174). Here, GCGR is linked to obesity due to melanocortin 4 receptor deficiency.